Prescient Therapeutics (ASX: PTX) is a clinical stage oncology company developing personalised medicine approaches to cancer, including targeted and cell therapies. Prescient’s universal CAR-T and targeted therapies are both personalised medicine approaches that seek to improve patient outcomes and provide new tools for clinicians in combating cancer.

PharmAust (ASX:PAA) is a clinical-stage biotechnology company developing new therapeutics for human and animal health applications. The company is repurposing monepantel for the treatment of cancer in dogs and neurodegenerative diseases in humans.

Monepantel is an approved veterinary product for the treatment of worm infestations in sheep. In mammalian cells, monepantel is a potent inhibitor of the mTOR pathway. The mTOR pathway plays a central role in cell growth and proliferation of cancer cells and in degenerating neurons. The mTOR pathway regulates the cellular “cleaning process”, where toxic protein is broken down into macromolecules to be reused. This autophagic process is disrupted in in most neurodegenerative diseases, including motor neurone disease.

PharmAust has an extensive patent portfolio with multiple ‘methods of use’ patents granted and filed covering the use of monepantel as a novel anti-cancer agent and for the treatment of neurodegenerative diseases.

Neurotech International (ASX:NTI) is a biopharmaceutical company focused on the development & commercialisation of neurological solutions that improve quality of life. NTI’s current focus is their world-first clinical study utilising NTI164 in the treatment for paediatric Autism Spectrum Disorder (ASD).

The Company is also focused on commercialising Mente, the world’s first home therapy that is clinically proven to increase engagement and improve relaxation in autistic children with elevated Delta band brain activity.

Island Pharmaceuticals is a drug research and repurposing company, focused on developing preventative or therapeutic drugs for viral infections.

We have a lead asset – ISLA-101 – that was initially developed by our wholly owned subsidiary, Isla Pharmaceuticals. ISLA-101 is a drug with a well-established safety profile, being repurposed for the prevention and treatment of dengue fever and other mosquito (or vector) borne diseases.

Dengue fever is the very definition of an unmet medical need. While 390 million humans are infected each year, it is thought that around 30-50% people with the disease do not present with symptoms, enabling the virus to spread within communities. Warming global climates are accelerating the presence of mosquito-borne viruses that can cause death to the US, Europe and Australia

There is no specific pharmaceutical treatment and the one vaccine which exists is available to a highly restricted audience.

Island has repurposed ISLA-101, an antiviral oral drug to treat mosquito-borne viruses (eg dengue fever / Zika) and is planning to move forward with Phase II studies with a significantly de-risked clinical program.

BCAL Diagnostics Limited (ASX:BDX) is an Australian biotechnology company committed to improved health outcomes for women. Over the past decade, BCAL has developed a non-invasive blood screening technology that is initially intended to be used alongside breast cancer screening methods, with results to date demonstrating 90% sensitivity and 85.5% specificity. The technology will initially complement current imaging technologies, such as the mammogram, while BCAL further progresses the development of a monitoring and screening test suitable for women of all ages and backgrounds in any location.

With more than two million new cases of breast cancer diagnosed globally each year, a substantial opportunity exists for BCAL to improve patient outcomes. BCAL has partnered with Precion Inc. to optimise protocols and procedures for the clinical studies required for regulatory approvals across several jurisdictions, commercialisation and market entry points.

Founded in 2010, BCAL is headquartered in Sydney and listed on the Australian Securities Exchange.

The Calmer Co provides natural solutions to calm nerves, support mind & muscle relaxation and induce sleep. Delivered to consumers via functional beverages, drinking powders, teas, shots and concentrates. The company distributes the following brands: Fiji Kava, Taki Mai & Danodan Hempworks.

CARETEQ (ASX:CTQ) is an Australian company with a focus on delivering best in class technology solutions for Health and Aged Care for a global audience.

Read more at careteq.com.au

Antisense Therapeutics is an Australian publicly-listed biotechnology company, developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases. 

Read more at antisense.com.au

Island Pharmaceuticals is a drug research and repurposing company, focused on developing preventative or therapeutic drugs for viral infections

Dengue fever is the very definition of an unmet medical need. While 390 million humans are infected each year, it is thought that around 30-50% people with the disease do not present with symptoms, enabling the virus to spread within communities. Warming global climates are accelerating the presence of mosquito-borne viruses that can cause death to the US, Europe and Australia

Read more at www.islandpharmaceuticals.com

Arovella Therapeutics (ASX: ALA) is a biotechnology company focused on developing therapies to treat human disease. Our two focus areas are oncology and conditions that impact the central nervous system.

Read more at www.arovella.com